CURRICULUM VITAE - Stanford University School of Medicine

Transcriptase Genotype After Multiple, Sequential Nucleoside Analog Drugs and the
Response to HAART in ACTG 364 (Abstract 138). Presented at the 6 th National
Retrovirus Conference, Chicago Feb 1-3, 1999.
58. D Katzenstein, H Guevara, M Hendry, T Gittens, L Zijena, M Mbizvo. Maternal HIV-1
RNA and V3 Antibodies Predict Risks For Vertical Transmission and Mortality In
Subtype C Virus Infection. (Abstract 235). Presented at the 6 th National Retrovirus
Conference, Chicago Feb 1-3, 1999.
59. H Guevara, O Tobaiwa, K Mohhamed, P Mason, M Hendry, D Katzenstein
HIV RNA in Maternal and Cord Plasma. Evidence for in utero prenatal transmission of
Subtype C HIV-1 infection in Zimbabwe. Presented at the 6 th National Retrovirus Conference, Chicago
Feb 1-3, 1999.
60. Morris MK, Hanson C, Hendry M, Israelski D, Zolopa AR, Tenney R, Guevara H, Tan G, Katzenstein D.
Antibody Titers Prior to HAART Predict Treatment Outcome. 6th Conference on Retroviruses and
Opportunistic Infections. Chicago, IL 1999 (Abstract 353)
61. R Machekano, M Bassett, W McFarland and D Katzenstein. Clinical Signs and Symptoms of Subtype C
HIV infection and predictors of mortality among heterosexual men in Harare, Zimbabwe.13 th
International AIDS Conference, Durban, South Africa.
62. L Gwanzura, R Machekano, M Bassett, W McFarland and D Katzenstein HIV1 / HSV-2 co-infection and
sero-concordance among heterosexual couples in Harare, Zimbabwe13 th International AIDS
Conference, Durban, South Africa.
63. Shulman N, Zolopa A, Murlidharan U, Israelski D, Brosgart C, Miller M, Van Doren S, Shafer R,
Katzenstein D. Salvage therapy with an efavirenz (EFV) and adefovir (ADV)-based regimen in
antiretroviral experienced patients. Abstract 13 in 2 nd International Workshop on Salvage Therapy for
HIV Infection, May 19-21, 1999, Toronto. (Oral Presentation). Received Young Investigator Scholarship
for travel and meeting fees.
64. Shulman N, Zolopa A, Murlidharan U, Israelski D, Brosgart C, Miller M, Shafer R, Katzenstein D.
Responses to salvage therapy with an efavirenz and adefovir-based regimen in antiretroviral
experienced patients: a genotypic study. Abstract 101 in 3 rd International Workshop on Drug
Resistance and Treatment Strategies, June 23-26, 1999, San Diego.
65. Shulman N, Zolopa A, Murlidharan U, Israelski D, Brosgart C, Miller M, Shafer R, Katzenstein D.
Efavirenz and adefovir-based salvage in antiretroviral experienced HIV+ patients. Abstract 2201 in 39 th
Interscience Conference on Antimicrobial Agents and Chemotherapy, Sep 26-29, 1999, San Francisco.
66. Shulman N, Zolopa A, King H, Whitcomb J, Passaro D, Israelski D, Shafer R, Katzenstein D,
Petropoulos C, Hellmann N. NNRTI hyper-susceptibility in a well-characterized cohort of treatment –
experienced patients receiving efavirenz and adefovir salvage regimens. Abstract 99 in 4 th International
Workshop on Drug Resistance and Treatment Strategies, June 12-16, 2000, Sitges, Spain.
67. Louie L, Graves A, Wells J, Hartogensis W, Jackman R, Zijenah L , Yiu C, Nguyen V, Schultz K,
Katzenstein D, Mason P. Genetic Influence on risk of active tuberculosis (TB) in Zimbabwe. (poster
presentation) 33 rd Annual Meeting of the Society for Epidemiologic Research, Seattle, WA, June, 2000.
68. Louie L, Hartogensis W, Jackman R, Zijenah L, Yiu C, Nguyen V, Schultz K, Katzenstein D, Mason P.
HLA and risk of tuberculosis in Zimbabwe. (oral presentation) 26 th Annual Meeting of the American
Society for Histocompatibility and Immunogenetics, Orlando, FL, Oct. 2000.
.
69. J. LATHEY*, C. TIERNEY, S. CHANG, R. D'AQUILA, S. HAMMER, D. KATZENSTEIN, and the ACTG
175 Genotype Team. NIAID, Bethesda, MD Homozygous Mutations in 3'A SDF-1 Are Associated with
More Rapid Disease Progression (Abstract 853). The 7th National Conferernce on Retrovirsuses and
Opportunistic Infections, San Francisco, CA January 30-February 4, 2000
25